Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dienogest - Bayer HealthCare Pharmaceuticals

Drug Profile

Dienogest - Bayer HealthCare Pharmaceuticals

Alternative Names: Visanne; BAY 865258; Dinagest; Endometrion®; M 18575; MJR-35; SH T00660AA; STS 557; Visanne

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Bayer Zydus Pharma; Mochida Pharmaceutical
  • Class Estrenes; Hormonal replacements; Oral contraceptives; Small molecules; Steroids; Testosterone congeners
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dysmenorrhoea; Endometriosis; Menopausal syndrome; Pregnancy
  • Phase III Adenomyosis

Most Recent Events

  • 22 Mar 2021 Launched for Endometriosis in India (PO) before March 2021 (Bayer Zydus Pharma website, March 2021)
  • 21 Mar 2021 Registered for Endometriosis in India (PO) before March 2021 (Bayer Zydus Pharma website, March 2021)
  • 24 Jan 2020 Launched for Dysmenorrhoea in Japan (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top